Pfizer (PFE)
23.46
-0.03 (-0.13%)
NYSE · Last Trade: Jun 3rd, 3:50 AM EDT

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.
Via The Motley Fool · June 3, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.
Via The Motley Fool · June 2, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers.
Via StockStory · June 1, 2025

The business may be somewhat boring, but it consistently delivers year after year, resulting in tremendous long-term returns.
Via The Motley Fool · June 1, 2025

Via Benzinga · May 29, 2025

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 trial.
Via Benzinga · May 30, 2025

Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Via StockStory · May 30, 2025
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.
Via Benzinga · May 27, 2025
Via The Motley Fool · May 27, 2025
Pfizer has taken its lumps lately. It's time to wonder whether the stock can make a comeback.
Via The Motley Fool · May 24, 2025
Via The Motley Fool · May 24, 2025
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.
Via The Motley Fool · May 24, 2025
Pfizer's high dividend yield warrants scrutiny regarding its sustainability, given changing revenues and pipeline investments.
Via MarketBeat · May 23, 2025
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums).
That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
Via StockStory · May 23, 2025
Via Benzinga · May 22, 2025
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.
Via Benzinga · May 21, 2025
Via The Motley Fool · May 21, 2025
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · May 20, 2025
Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.
Via Benzinga · May 20, 2025
The agency plans to demand stronger evidence of efficacy for the shots before approval is granted for healthy persons, between the ages of six months and 64 years, with no risk factors for severe COVID-19 infection.
Via Stocktwits · May 20, 2025
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness.
Via Investor's Business Daily · May 20, 2025